PracticeUpdate Conference Series: IID 2018

" Both HLA-

Cw6-positive (n=260, 50.1%) and HLA- Cw6-negative (n=259, 49.9%) patients demonstrated good response to guselkumab: 83% vs 77% achieved ≥90% improvement over baseline

The largest differences in the proportion of responders between the two groups were observed at week 8 (18%) for PASI 90 and at week 20 (15.2%) for PASI 100 responses. Dr. Liu concluded that the results demonstrated a distinct, but modest, positive association between response to interleukin 23 blockade with gusel- kumab and HLA-Cw6-positive status among patients with psoriasis.

At baseline, subjects exhibited a median affected body surface area of approximately 21% and median PASI score of 19. A total of 18% had a history of psoriatic arthritis. Approximately 24% of subjects scored severe on investigator’s global assessment. In both trials, 23% had received prior biologic systemic therapy In the present study, HLA-Cw6 genotype status was determined using a method based on poly- merase chain reaction. Responses to guselkumab were evaluated at weeks 2, 4, 12, 16, 20, 24, and 28 in 519 Caucasian patients stratified by HLA-Cw6 status. Potential associations between several base- line clinical variables and responses were also evaluated. Variables demonstrating statistical significance were included as covariates in multivariate regression models that evaluated the association between HLA-Cw6 status and response to guselkumab. Both HLA-Cw6-positive (n=260, 50.1%) and HLA-Cw6-negative (n=259, 49.9%) patients demon- strated good response to guselkumab: 83% vs 77% achieved ≥90% improvement over baseline in PASI 90 at week 28, respectively. HLA-Cw6-positive patients achieved PASI 90 response more rapidly and were more rapidly and likely to achieve skin clearance because this group contained a significantly higher percentage of PASI 90 responders at weeks 8, 12, 16, and 20; as well as PASI 100 responders at weeks 8, 12, 16, 24, and 28, vs the HLA-Cw6-negative group.

in PASI 90 at week 28, respectively.

"

www.practiceupdate.com/c/68272

Courtesy of IID 2018

© Courtesy of IID 2018

IID 2018 • PRACTICEUPDATE CONFERENCE SERIES 21